TYUMEN, November 10, UralPolit.Ru. Last week, the Russian government decided to simplify the drug labeling process. As it became known, on November 2, Russian Prime Minister Mikhail Mishusti signed a decree to simplify the procedure for "working with the drug movement monitoring system." However, such a measure is temporary. Simply put, this decision was made in order to eliminate the drug shortage. Including in the Tyumen region. This is reported on the official website of the national labeling system "Honest Mark". According to the document, for example, pharmacists no longer need to wait for confirmation from the labeling system for information about the acceptance of drugs, they can be sold through cash desks and registrars right away. Pharmacists will not need to wait for confirmation from suppliers either. The system of importing and moving drugs into the country will also be simplified. Such a decision will increase the speed of operations with drugs, which means it will reduce the shortage of drugs. The head of the territorial body of Roszdravnadzor in the Tyumen region, Khanty-Mansi Autonomous Okrug-Yugra and Yamal-Nenets Autonomous Okrug Elena Levkina clarified that the failures arising in the system of labeling and registration of drugs "Honest Sign" impeded the sale of drugs. especially those for which there is an increased demand. In other words, drugs for the prevention or treatment of coronavirus or seasonal respiratory diseases. “Requests to the system were processed for a very long time. In some regions, this process took several weeks. Therefore, pharmacies and wholesalers could not sell medicines. After the government's decision to temporarily simplify labeling, the situation has changed for the better - drugs are beginning to appear in the retail network, "Tyumenskaya Liniya quotes Elena Levkina. However, the shortage of" colds "and" covid "drugs has not yet been completely overcome. This is due to seasonal morbidity and the difficult situation with the coronavirus, which leads to increased demand and rapid sales of drugs. At the same time, medical manufacturers are increasing the number of drugs, including those intended for the treatment of COVID-19.